Journée Collaborative 2025

14 oct. 2025 | Lyon, France

GERALDINE LE DUC

CEO/cofondatrice

NH TherAguix

Grenoble, France

4 visites de profilIntervenantLes non-membres - avec rendez-vous B2B

Chercheur (PhD, HDR, 120 articles, 7 brevets) CEO/cofondatrice NHT TherAguix (€30M dilutifs, 20 FTE, Phase 2) Presidente Therasonic Senior Advisor Accélérateur

Mon organisation

NH TherAguix

NH TherAguix

PME / Start-ups

Grenoble, France

NH TherAguix , a Phase 2 biotech company, has developed an innovative nano drug AGuIX® to improve cancer treatment by radiotherapy to treat tumours and metastases. Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential. AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereo-radiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA). NH TherAguix was established in 2015 after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radioenhancement effect. Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.
En savoir plus

Sur moi

Réseaux sociaux

Sessions d'intervenants 1

mardi 14 octobre 2025

14:30 - 16:30

Table ronde 5 | De l'idée labo à la solution santé : mobiliser les expertises pour accélérer le développement des start-ups en santé

Lieu :Salle de commission 8/9Track :Tables rondes

soutenue par le Pôle Universitaire d'Innovation Grenoble Alpes